Advanced Medical Solutions Group Regulatory News (AMS)

            2 October 2023

 

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Appointment of Chair

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces the appointment of Liz Shanahan, a current Non-Executive Director of AMS, as Chair of the Board. Liz will succeed current Chair Peter Allen on 1 January 2024, following a handover period. As previously communicated, Peter Allen is stepping down after ten years with the Group.

 

Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. She is currently a Non-Executive Director of AIM-listed businesses Inspiration Healthcare Group plc (LON: IHC) and Celadon Pharmaceuticals plc (LON: CEL) and was previously Non-Executive Director of UDG Healthcare plc until its £2.8 billion takeover in August 2021. Between 2011 and 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London and a member of the organisation's Innovations Advisory Board. Alongside her Board appointments she is a business advisor and Executive coach.

 

Upon appointment, Liz Shanahan will replace Peter Allen as Chair of the Nomination Committee. A search is underway for the appointment of an additional independent Non-Executive Director.

 

Chris Meredith, Chief Executive Officer of AMS, commented: "We look forward to welcoming Liz as Chair in January. Her many years of life sciences experience and significant contribution to AMS since joining as a Non-Executive Director made her the ideal candidate to now lead the Board from 2024 onwards. Having worked with Liz for the past years, I know the benefit, insight and strategic guidance Liz will bring as we work closely together to execute the AMS growth strategy.

 

"I want to express my personal thanks to Peter Allen. His commitment, passion and advice have been invaluable over the past ten years and he has led the Board through a significant period of growth. He will depart with our best wishes for the future."

 

Liz Shanahan, commenting on her new role, said: "I am delighted to assume the role of Chair of AMS during this pivotal time for the business, with entry into new markets and product categories on the near horizon. It is clear to me that the business has the ambition and capabilities to execute on the attractive long-term growth opportunities in its markets. This is underpinned by the team's drive and expertise. I look forward to working with Chris Meredith, the Executive team and the rest of the Board, for the benefit of all our stakeholders."

 

Peter Allen, departing Chair, commented: "I am proud of what AMS has achieved during my time as Chair, particularly the integration of several acquisitions, expansion of both the surgical and woundcare businesses and the benefit we have brought for patients and payors through this. It has been a privilege to spend ten enjoyable and successful years with this great business, but it is now time to hand on the baton of Chair. I look forward to following AMS' progress in the coming months and years."

 

 

 

- End -

 

For further information, please visit www.admedsol.com or contact:

 

 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see  www.admedsol.com.